Clinical Trials Using Leuprolide Acetate

Clinical trials are research studies that involve people. The clinical trials on this list are studying Leuprolide Acetate. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-21 of 21
  • Antiandrogen Therapy and Radiation Therapy with or without Docetaxel in Treating Patients with Prostate Cancer That Has Been Removed by Surgery

    This randomized phase II / III trial studies docetaxel, antiandrogen therapy, and radiation therapy to see how well it works compared with antiandrogen therapy and radiation therapy alone in treating patients with prostate cancer that has been removed by surgery. Androgen can cause the growth of prostate cells. Antihormone therapy may lessen the amount of androgen made by the body. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving antiandrogen therapy and radiation therapy with or without docetaxel after surgery may kill any remaining tumor cells.
    Location: 240 locations

  • Standard Systemic Therapy with or without Definitive Treatment in Treating Participants with Metastatic Prostate Cancer

    This phase III trial studies whether the addition of definitive treatment (radiation or surgical removal) of the primary tumor to standard systemic therapy for patients with prostate cancer, may help prevent the cancer from the spreading to other parts of their body. Removing the prostate by either surgery or radiation therapy in addition to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.
    Location: 179 locations

  • A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

    This is a randomized, open-label, three-arm, phase 3 study in men with biochemically recurrent prostate cancer and PSA doubling time ≤ 9 months at the time of study entry.
    Location: 27 locations

  • Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutation With Advanced Breast Cancer Who Have Progressed on or After Prior Treatments

    Study assessing the efficacy and safety of alpelisib plus fulvestrant or letrozole, based on prior endocrine therapy, in patients with PIK3CA mutation with advanced breast cancer who have progressed on or after prior treatments
    Location: 15 locations

  • Apalutamide, Abiraterone Acetate, Prednisone, Leuprolide Acetate, and Stereotactic, Ultra-hypofractionated Radiation Therapy in Treating Patients with Very High Risk Prostate Cancer

    This phase II trial studies how well apalutamide, abiraterone acetate, prednisone, leuprolide acetate, and stereotactic, ultra-hypofractionated radiation therapy work in treating patients with very high risk prostate cancer. Hormone therapy using apalutamide, abiraterone acetate, prednisone, and leuprolide acetate may fight prostate cancer by lowering the amount of androgen the body makes and / or blocking the use of androgen by the tumor cells. Stereotactic, ultra-hypofractionated radiation therapy is a type of radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Giving apalutamide, abiraterone acetate, prednisone, and leuprolide acetate, and stereotactic, ultra-hypofractionated radiation therapy may work better in treating patients with prostate cancer.
    Location: 10 locations

  • A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease

    The purpose of this trial is to test if a marketed drug for advanced prostate cancer (FIRMAGON) can reduce the risk of cardiovascular complications as compared to another marketed drug for advanced prostate cancer (LUPRON DEPOT) in patients with prostate cancer and cardiovascular disease.
    Location: 8 locations

  • A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer

    The purpose of this study is to determine the benefit and safety of relugolix 120 mg orally once daily for 48 weeks on maintaining serum testosterone suppression to castrate levels (≤ 50 ng / dL [1.7 nmol / L] in patients with androgen-sensitive advanced prostate cancer.
    Location: 2 locations

  • Testosterone Therapy Followed by Enzalutamide or Abiraterone Acetate in Treating Patients with Prostate Cancer That Is Progressing on Combined Androgen Therapies

    This phase II trial studies how well testosterone therapy followed by enzalutamide or abiraterone acetate works in treating patients with prostate cancer that has become worse or spread on combined androgen therapies. Androgens, such as testosterone, can cause the growth of prostate cancer cells. Androgen therapies, such as enzalutamide and abiraterone acetate, suppress or block the production or action of testosterone. Rapid treatment with testosterone may make the cancer cells become sensitive to retreatment with enzalutamide or abiraterone acetate. Giving testosterone prior to enzalutamide or abiraterone acetate may have an effect on the growth of prostate cancer in men who have not responded to long term therapy to lower testosterone in their blood (castrating therapy).
    Location: 2 locations

  • Androgen Deprivation Therapy (Leuprolide and Degarelix) and Chemoimmunotherapy (Cemiplimab and Docetaxel) for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer

    This phase II trial studies the side effects of androgen deprivation therapy (leuprolide and degarelix) and chemoimmunotherapy (cemiplimab and docetaxel) and to see how well they work in treating patients with hormone-sensitive prostate cancer that has spread to other places in the body (metastatic). Androgen can cause the growth of prostate cancer cells. Hormone therapy using leuprolide and degarelix may fight prostate cancer by blocking the use of androgen by the tumor cells. Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The purpose of this study is to determine if the addition of immunotherapy to chemotherapy and androgen deprivation therapy, is safe and improves response to therapy.
    Location: NYP / Columbia University Medical Center / Herbert Irving Comprehensive Cancer Center, New York, New York

  • A Trial to See What the Results Are for Radiation Therapy and Hormone Therapy vs Radiation Therapy With Enhanced Hormone Therapy With Enzalutamide for Patients With PSA Recurrence After Surgery

    Patients with post-prostatectomy PSA (Prostate Specific Antigen) recurrences with aggressive disease features will receive salvage radiation therapy and standard androgen deprivation therapy (ADT) or enhanced ADT to determine if there is any improvement in progression-free survival when enhanced ADT is used compared to standard ADT.
    Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri

  • GnRH analog, Abiraterone Acetate, and Prednisone in Treating Patients with Stage IV Castration Resistant Prostate Cancer

    This phase Ib trial studies how GnRH analog, abiraterone acetate, and prednisone work in treating patients with stage IV castration resistant prostate cancer. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as GnRH analog, abiraterone acetate, and prednisone may lessen the amount of androgen made by the body.
    Location: Moffitt Cancer Center, Tampa, Florida

  • Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients with Metastatic Prostate Cancer

    This phase 2 trial studies radium Ra 223 dichloride, hormone therapy and stereotactic body radiation in treating patients with prostate cancer that has spread to other places in the body. Radium Ra 223 dichloride contains a radioactive substance that collects in the bone and gives off radiation that may kill cancer cells. Hormone therapy using leuprolide acetate or goserelin acetate may fight prostate cancer by lowering the amount of testosterone the body makes. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Giving radium Ra 223 dichloride, hormone therapy and stereotactic body radiation may work better at treating prostate cancer.
    Location: City of Hope Comprehensive Cancer Center, Duarte, California

  • Androgen Deprivation Therapy, Pembrolizumab, and Stereotactic Body Radiation Therapy with or without TLR9 Agonist SD-101 in Treating Patients with Metastatic Prostate Cancer

    This randomized phase II trial studies how well androgen deprivation therapy, pembrolizumab, and stereotactic body radiation therapy with or without TLR9 agonist SD-101 in treating patients with prostate cancer that has spread to other places in the body. Androgen can cause the growth of tumor cells. Androgen deprivation therapy, such as leuprolide acetate, prednisone, and abiraterone acetate may lessen the amount of androgen made by the body. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Colony-stimulating factors, such as TLR9 agonist SD-101, may increase the production of blood cells. It is not yet known whether giving androgen deprivation therapy, pembrolizumab, and stereotactic body radiation therapy with or without TLR9 agonist SD-101 may work better in treating patients with prostate cancer.
    Location: UCSF Medical Center-Mount Zion, San Francisco, California

  • Apalutamide with or without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients with High-Risk Prostate Cancer Undergoing Surgery

    This randomized phase II trial studies how well apalutamide works with or without abiraterone acetate, gonadotropin-releasing hormone agonist, and prednisone in treating patients with high-risk prostate cancer undergoing surgery. Androgen can cause the growth of prostate cancer cells. Hormone therapy using apalutamide, abiraterone acetate, and gonadotropin-releasing hormone analog (GnRH agonist) may fight prostate cancer by lowering the levels of androgen the body makes. Prednisone may either kill the tumor cells or stop them from dividing. Giving apalutamide with or without abiraterone acetate, GnRH agonist and prednisone may work better in treating patients with prostate cancer.
    Location: 2 locations

  • Androgen Receptor Antagonist ARN509 and Leuprolide Acetate in Treating Patients with Prostate Cancer before Surgery

    This phase II trial studies how well androgen receptor antagonist ARN-509 and leuprolide acetate work in treating patients with prostate cancer before surgery. Hormone therapy using androgen receptor antagonist ARN-509 and leuprolide acetate may fight prostate cancer by lowering the amount of androgen the body makes and / or blocking the use of androgen by the tumor cells.
    Location: Case Comprehensive Cancer Center, Cleveland, Ohio

  • Hormone Therapy and Docetaxel before Surgery and Radiation Therapy in Treating Patients with Newly Diagnosed Oligometastatic Prostate Cancer

    This phase II trial studies the side effects of hormone therapy and docetaxel before surgery and radiation therapy in treating patients with newly diagnosed prostate cancer that has spread from the primary tumor through the body to form a small number of new tumors in one or two other parts of the body. Androgens are a type of hormone that can cause the growth of prostate cancer cells. Androgen deprivation therapy, stops the growth of tumor cells by lessening the amount of androgens made by the body. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving androgen deprivation therapy and chemotherapy before radical prostatectomy may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving radiation therapy after surgery may kill any remaining tumor cells. Stereotactic body radiation therapy (SBRT) uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Giving androgen deprivation therapy and chemotherapy before surgery and SBRT may work better in treating patients with newly diagnosed oligometastatic prostate cancer.
    Location: Johns Hopkins University / Sidney Kimmel Cancer Center, Baltimore, Maryland

  • High-Dose Brachytherapy in Treating Patients with Prostate Cancer

    This phase I / II trial studies the side effects and how well high-dose brachytherapy works in treating patients with prostate cancer that has not spread to other parts of the body. Brachytherapy is a type of radiation therapy in which radioactive material sealed in needles, seeds, wires, or catheters is placed directly into or near a tumor and may be a better treatment in patients with prostate cancer.
    Location: Stanford Cancer Institute Palo Alto, Palo Alto, California

  • Intensity Modulated Radiation Therapy with Stereotactic Radiosurgery Boost and Hormone Therapy in Treating Patients with Prostate Cancer

    This phase I trial studies intensity modulated radiation therapy (IMRT) with stereotactic radiosurgery boost and hormone therapy in treating patients with prostate cancer. Specialized radiation therapy, such as IMRT and stereotactic radiosurgery, that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Androgen hormones can cause the growth of prostate cancer cells and antihormone therapy drugs, such as leuprolide acetate, goserelin acetate, and bicalutamide, may lessen the amount of androgens made by the body. Giving IMRT with stereotactic radiosurgery boost and androgen deprivation therapy may be an effective treatment for prostate cancer.
    Location: University of California Davis Comprehensive Cancer Center, Sacramento, California

  • Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer

    This is a trial for patients with newly diagnosed metastatic prostate cancer with 5 or fewer sites of metastases. The trial involves surgery (removal of the prostate), six months of hormone therapy, and stereotactic body radiotherapy to the sites of metastasis.
    Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

  • Antiandrogen Therapy and SBRT in Treating Patients with Recurrent, Metastatic Prostate Cancer

    This phase II trial studies how well antiandrogen therapy (leuprolide, apalutamide, and abiraterone acetate) and stereotactic body radiation therapy (SBRT) works in treating patients with prostate cancer that has come back and has spread to other parts of the body. Drugs used in chemotherapy, such as leuprolide, apalutamide, and abiraterone acetate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Giving antiandrogen therapy and SBRT may work better in treating patients with prostate cancer.
    Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

  • Palifermin with Leuprolide Acetate or Degarelix after Total-Body Irradiation Based Donor Stem Cell Transplant in Treating Patients with Hematologic Malignancies

    This phase II trial studies how well palifermin with leuprolide acetate or degarelix works after total body-irradiation based donor stem cell transplant in treating patients with hematologic malignancies. Giving chemotherapy and total body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving palifermin and leuprolide acetate or degarelix and removing the T cells from the donor cells before transplant may stop this from happening. It is not yet known whether giving palifermin with leuprolide acetate or degarelix is more effective in helping the immune system recover faster after a donor stem cell transplant.
    Location: Memorial Sloan Kettering Cancer Center, New York, New York